INTRODUCTION:
Alzheimer's disease (AD) is the most common form of age-related dementia, characterized by cognitive impairment, neurodegeneration, b-amyloid (Ab) deposition, neurofibrillary tangle formation, and neuroinflammation. The most popular therapeutic approach aimed at reducing Ab burden has not yet proved effective in halting disease progression. A successful therapy would both remove the pathological hallmarks of the disease and provide some functional recovery. The hippocampus contains neural progenitor cells that continue to generate new neurons, a process called adult hippocampal neurogenesis (AHN). AHN is impaired before the onset of classical AD pathology in AD mouse models. Human AHN has also been reported to be altered in AD patients. However, evidence supporting a role for AHN in AD has remained sparse and inconclusive.
RATIONALE: Two fundamental questions remain: (i) whether AHN could be enhanced and exploited for therapeutic purposes for AD, and (ii) whether AHN impairment mediates aspects of AD pathogenesis. To address these questions, we increased AHN genetically (WNT3) and pharmacologically (P7C3) in AD transgenic 5×FAD mice and explored whether promoting AHN alone can ameliorate AD pathology and behavioral symptoms. We assessed the role of exercise, a known neurogenic stimulus, and explored whether promoting AHN in conjunction with the salutary biochemical changes induced by exercise can improve AD pathology and behavioral symptoms in mice. We also investigated whether AHN suppression, by irradiation, temozolomide, or dominantnegative WNT, contributes to AD pathogenesis and assessed the functional roles of AHN in AD.
RESULTS: Inducing AHN alone conferred minimal to no benefit for improving cognition in 5×FAD mice. Exercise-induced AHN improved cognition along with reduced Ab load and increased levels of brain-derived neurotrophic factor (BDNF), interleukin-6 (IL-6), fibronectin type III domain-containing protein-5 (FNDC5), and synaptic markers. However, AHN activation was also required for exercise-induced improvement in memory. Inducing AHN genetically and pharmacologically in combination with elevating BDNF levels mimicked beneficial effects of exercise on AD mice. Conversely, suppressing AHN in early stages of AD exacerbated neuronal vulnerability in later stages of AD, leading to cognitive impairment and increased neuronal loss. However, no such effects from AHN ablation were observed in nontransgenic wild-type (WT) mice, suggesting that AHN has a specific role in AD.
CONCLUSION: Promoting AHN can only ameliorate AD pathology and cognitive deficits in the presence of a healthier, improved local brain environment, e.g., stimulated by exercise. Increasing AHN alone combined with overexpression of BDNF could mimic exerciseinduced improvements in cognition, without reducing Ab burden. Adult-born neurons generated very early in life are critical for maintaining hippocampal neuronal populations in the hostile brain environment created by AD later in life. Thus, AHN impairment may be a primary event that later mediates other aspects of AD pathogenesis. Future attempts to create pharmacological mimetics of the benefits of exercise on both increased AHN and BDNF may someday provide an effective means for improving cognition in AD. Moreover, increasing neurogenesis in the earliest stages of AD pathogenesis may protect against neuronal cell death later in the disease, providing a potentially powerful disease-modifying treatment strategy for AD. A lzheimer's disease (AD) is the most common form of age-related dementia, characterized by cognitive impairment, neurodegeneration, deposition of b-amyloid (Ab), neurofibrillary tangle formation, and neuroinflammation (1) . The most popular therapeutic approach aimed at reducing Ab burden has not yet proved effective in halting disease progression. A successful therapy would ideally both remove the pathological hallmarks of the disease and provide a level of functional recovery.
The human hippocampus contains neural progenitor cells (NPCs) that continue to generate new neurons, a process called adult hippocampal neurogenesis (AHN) (2) . Although adult-generated neurons play an important role in learning and memory under physiological conditions, their function under pathological conditions, such as those of AD, has remained elusive. Emerging evidence indicates that AHN is impaired prior to the onset of classical AD pathology in AD mouse models, e.g., Ab deposition (3) . Human AHN has also been reported to be altered in AD patients (4) (5) (6) (7) (8) (9) .
To date, however, the evidence supporting a role for AHN in AD has remained sparse and inconclusive. Two fundamental questions remain: (i) whether AHN could be enhanced and exploited for therapeutic purposes for AD, and (ii) whether AHN impairment mediates aspects of AD pathogenesis or is a neuroadaptive response to the complex pathological events of the disease. We set out to address these two questions genetically and pharmacologically in 5×FAD mice (10) . We also assessed the role of physical exercise, a known neurogenic stimulus that counteracts various aspects of AD pathology (11) (12) (13) , and explored whether promoting AHN in conjunction with the salutary biochemical changes that are induced by exercise can ameliorate AD pathology and behavioral symptoms in mice. Finally, we investigated how impairment of AHN contributes to AD pathogenesis and assessed the functional roles of adult-generated neurons in the pathological course of AD.
AHN stimulation with LV-Wnt3 and P7C3 or with exercise
To stimulate AHN, beginning at 2 months of age for 4 or 4.5 months, sedentary 5×FAD mice were injected with P7C3, a compound that enhances NPC survival (14) . At the 3-month time point, these mice also received lentivirus expressing WNT3 protein (LV-Wnt3) to increase NPC proliferation (15) (Fig. 1, A and B) . Control 5×FAD mice were injected with vehicle and lentivirus expressing green fluorescent protein (LV-GFP, referred to as "5×FAD CTL " mice). As an alternative means of inducing AHN, we also tested the effects of exercise on a 5×FAD mice cohort. Successful promotion of AHN with P7C3 and LVWnt3 or with exercise was observed in the male and female 5×FAD mice, as determined by immunostaining for doublecortin (DCX) + neurons ( Fig. 1 , C and D). After completing cognition tasks, mice with similar DCX + cell counts among the 5×FAD mice treated with P7C3 and LV-Wnt3 and the exercised 5×FAD mice were selected for further study; we included all those with levels higher than the maximum level seen in 5×FAD CTL mice (mice in dashed box in Fig. 1D ; see table S1 for animal numbers in each experimental group and group arrangement explanations). From here on, we refer to the subsets of 5×FAD mice treated with P7C3 and LV-Wnt3 to promote AHN or exercised 5×FAD mice in the box in Fig. 1D as "5×FAD
ProAHN
" and "5×FAD +AHN(RUN) " mice, respectively. Exercised 5×FAD mice with less than the maximum DCX + cell count seen in 5×FAD CTL mice were designated "5×FAD yAHN(RUN) " mice. Mice were sacrificed at the age of 6 to 6.5 months, when untreated 5×FAD mice showed cognitive deficits compared to nontransgenic wild-type mice (WT) mice ( fig. S1 ). Endogenous neurogenic changes and AD pathologies observed in untreated 5×FAD mice, including our rationale for employing this mouse line, are described in figs. S2 and S3 and materials and methods.
We tested whether AHN stimulation by exercise versus P7C3 and LV-Wnt3 affected Ab plaque amounts. Immunostaining with anti-Ab antibody 3D6 showed that, whereas exercised mice exhibited a decreased Ab burden, activation of AHN alone (by P7C3 and LV-Wnt3) did not change Ab plaque amounts (Fig. 1, C and E). 5×FAD yAHN(RUN) mice also had a reduced Ab burden, suggesting that an effect due to exercise and not AHN alone contributed to changes in Ab burden after physical activity.
Increasing AHN alone did not ameliorate cognitive function in 5×FAD mice
We examined whether promoting AHN could ameliorate cognitive impairment in AD. We performed a delayed nonmatching to place (DNMP) task to measure spatial pattern separation, an eight-arm radial arm maze (RAM) to measure reference and retention memory, and a Y-maze to measure spatial working memory. Pattern separation, which is the formation of distinct representations of similar inputs, has been shown to require adult-generated neurons (16) . Reduced ability to separate patterns (i.e., to recognize differences between very similar events) is one of the first behavioral deficits in patients with mild cognitive impairments, which often progress to AD (17) . The other cognition types listed are well accepted to be hippocampus dependent; however, it remains unclear whether AHN contributes to these memory types. We used the RAM and Y-maze, which are routine methods to assess memory function in AD mice (18) , to explore whether increasing AHN also ameliorates AD-associated cognitive impairment in 5×FAD mice.
In the DNMP task, male cohorts of 5×FAD ProAHN and 5×FAD +AHN(RUN) mice showed similar improvements in pattern separation compared to 5×FAD CTL mice at 5.5 to 6 months of age ( Fig. 2A, left graph) . However, in female cohorts, 5×FAD ProAHN mice failed to show improved pattern separation memory compared to 5×FAD CTL mice, whereas 5×FAD +AHN(RUN) mice showed improvement ( Fig. 2A, right graph) . Both male and female 5×FAD ProAHN mice failed to show improved working memory in the Y-maze, whereas 5×FAD +AHN(RUN) mice performed better (Fig. 2B  and fig. S4 ). Male mice were tested in the RAM task. In the training trials of the task, all the groups showed a clear learning curve during the 5-day training session (Fig. 2C, left graph) , Fig. 2 ). This finding suggests that increased AHN above physiological levels is required for the positive behavioral effects of exercise in 5×FAD mice. However, a lack of AHN in WT mice does not block the beneficial behavioral effects of increased physical activity gained through living in an enriched environment (19) . We hypothesized that adult-generated neurons have specific functions in AD pathological conditions and in mediating the effects of exercise in AD. To test these points, we assessed the effects of AHN ablation in 5×FAD mice versus WT mice.
Ablating AHN induced cell death in dentate gyrus (DG) of 5×FAD mice
To block AHN, 6-to 8-week-old male WT and 5×FAD mice received either focal irradiation (20) , and 5×FAD
LV-dnWnt (High KD) mice (F (2,24) = 12.17, P < 0.01; right). , and 5×FAD LV-dnWnt (High KD) mice.
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the structural integrity of the DG specifically under pathological conditions of AD but not under normal physiological conditions. Enzyme-linked immunosorbent assay (ELISA) and immunoblot assays revealed that the levels of postsynaptic density 95 (PSD95) and synapseassociated protein 97 (SAP97) in the hippocampal homogenates of 5×FAD -AHN (High KD) mice were reduced compared to 5×FAD CTL mice at 5 months of age ( Fig. 4C and fig. S5 ). Meanwhile, AHN reduction did not change the levels of PSD95 and SAP97 in WT mice. These results demonstrate that suppressing AHN resulted in considerable loss of synaptic proteins PSD95 and SAP97 in the hippocampus of 5×FAD mice, likely due to DG neuronal cell death.
Golgi staining showed that the morphology of granule neurons in the outer granule cell layer, generated during early development, of 5×FAD IR mice did not differ from that of neurons of 5×FAD Sham mice ( Fig. 4D and fig. S6 ). Furthermore, Casp3
+ cell number did not increase in 5×FAD
-AHN (Mod KD) mice (Fig. 3F ). These results suggest that the increase in Casp3 + cells and loss of granule neurons and synaptic markers in 5×FAD
-AHN (High KD) mice can be attributed mostly to AHN loss, rather than the direct impact of IR, TMZ, or LV-dnWnt on the existing neurons in the more susceptible brain environment of 5×FAD mice. Five-month-old 5×FAD mice in which AHN was suppressed much later (at 4 to 4.5 months), and which had AHN levels similar to those of untreated 5×FAD mice before AHN was suppressed, exhibited only negligible Casp3 + cell numbers ( fig. S7A ). We also could not detect any significant Casp3
+ cell numbers in 3-month-old 5×FAD mice in which AHN was ablated starting at 1. that adult-generated neurons at a relatively early stage of AD (6 weeks to 4 months old) are critical for later maintaining the survival and stability of granule neurons (at 5 months and older). Thus, AHN impairment at a very early disease stage appears to initiate cell death in later stages, i.e., when the neuronal milieu becomes more hostile [e.g., elevated levels of Ab pathology, interleukin1b (IL-1b), tumor necrosis factor a (TNFa), and keratinocyte-derived chemokine (KC/GRO); reduced levels of brain-derived neurotrophic factor (BDNF); figs. S2 and S3]. Blocking AHN did not affect the levels of Ab deposition, numbers of Iba1 + microglia, or GFAP + astrocytes in the hippocampus of 5-month-old 5×FAD mice ( fig. S8 ), suggesting that AHN in 5×FAD mice had no effect on Ab pathology or gliosis.
Ablating AHN exacerbated cognitive impairment in 5×FAD mice
We next investigated whether cognitive dysfunction progressed more rapidly in the absence of AHN in 5×FAD mice. Untreated 5×FAD mice showed significant impairment in pattern separation at 5 months compared to age-matched WT mice, but not at 3 months of age ( fig. S1 ). Therefore, the impact of AHN loss on pattern separation memory was studied in WT -AHN and 5×FAD
-AHN mice at 3 months of age. In the DNMP task, both 3-month-old WT -AHN and 5×FAD S9 ). These results suggest that adult-generated neurons are required for pattern separation both in WT and 5×FAD mice. Thus, decreased AHN in AD is sufficient to cause impairment of this memory type, and other AD pathological factors are not required for this behavioral change.
In the RAM task, 5-month-old WT -AHN mice did not perform differently from WT CTL mice also showed impaired memory compared to 5×FAD
LV-GFP mice ( fig. S10 ). Five-month-old 5×FAD mice in which AHN was ablated starting at 4 to 4.5 months of age performed comparably to 5×FAD CTL mice in the RAM task ( fig. S11) . No impairment was observed in 3-month-old 5×FAD -AHN mice in which AHN was suppressed beginning at 1.5 to 2 months of age compared to those with AHN ( fig. S12 ). These results suggest that loss of AHN, alone, is not sufficient to cause global hippocampal cognitive deficits in 5×FAD mice, and that loss of mature granule neurons (owing to AHN loss at a much earlier age) is minimally required to result in global cognitive deficits later in life (beginning at 5 months of age).
Ablating AHN in male 5×FAD mice reduces hippocampal levels of TGF-b1
The mechanisms by which the lack of AHN contributes to cell death in mature neural populations in 5×FAD mice are likely diverse with multiple pathways, and future efforts will be necessary to elucidate them. Among the cytokines we measured, transforming growth factorb1 (TGF-b1) levels were significantly reduced in the hippocampal tissue homogenates of 5×FAD -AHN (High KD) mice compared to 5×FAD CTL mice ( Fig. 5A and table S5 ). TGF-b1 levels were not reduced in WT -AHN (High KD) mice compared to WT CTL mice ( fig. S13 ), suggesting that AHN loss, accompanied by loss of granule cells and synaptic markers, results in the reduced TGFb1 levels. TGF-b1 is an anti-inflammatory cytokine that increases rapidly after injury and with age (22) . Neurons and multipotent NPCs produce TGF-b1 (23, 24) , and TGF-b1 inhibits Casp3 (25) . We asked whether TGF-b1 has protective effects against cell death in AD, i.e., whether reduced TGF-b1 levels in 5×FAD
-AHN contribute to cell death. For this purpose, we increased TGF-b1 in 5×FAD
-AHN mice by injecting lentivirus expressing TGF-b1 (LV-TGF-b1; 5×FAD
, and 5×FAD
LV-dnWnt/LV-TGF-b1 ) and quantified Casp3 + cells (Fig. 5 , B to D). These mice experienced increased hippocampal TGF-b1 levels and decreased numbers of Casp3 + cells in the DG compared to 5×FAD mice without AHN that were injected with control LV-RFP (5×FAD   IR/LV-RFP   ,  5×FAD TMZ/LV-RFP , and 5×FAD
LV-dnWnt/LV-RFP ). However, Casp3 + cells were still evident in the 5×FAD -AHN mice injected with LV-TGF-b1, and increasing TGF-b1 levels was not sufficient to rescue cell death fully in 5×FAD mice without AHN. Our results suggest that TGF-b1 has protective effects against cell death in 5×FAD mice and that the reduced TGF-b1 levels in 5×FAD mice without AHN, at least in part, contribute to granule cell death. Other mechanisms that maintain existing neuronal stability in AD likely account for the fraction of cell death that was not rescued by TGF-b1. Increasing TGF-b1 in 5×FAD -AHN mice did not change the degree of AHN ( fig. S14 ), although TGF-b1 has been shown to regulate neurogenesis (26) (27) (28) (29) .
Protective effects of TGF-b1 against cell death were confirmed in three-dimensional (3D) cultures of differentiated human NPCs expressing familial AD-related mutations (3D-FAD cells) (30) . Our 3D-FAD cells showed an increased number of Casp3 + cells and endogenous neuronal loss, as indicated by cell counting, compared to control WT cells (3D-WT cells) beginning at 5 weeks of differentiation ( fig. S15 ). Six-week differentiated 3D-FAD cells were treated with TGF-b1 for up to 2 weeks, after which cell viability was assessed. Casp3 + cell number was significantly reduced in 3D-FAD cells treated with TGF-b1 (10 ng/ml; Fig. 5, E and F) . Treatment of TGF-b1 significantly increased cell survival in 3D-FAD cells, as indicated by cell counting (Fig. 5, G and H) . Furthermore, a lactate dehydrogenase (LDH) assay showed that treatment with TGF-b1 resulted in decreased LDH release ( fig. S16A ). Protective effects of TGF-b1 were also shown by a CellTiter-Glo luminescent assay, in which cell viability was increased with TGF-b1 treatment ( fig. S16B ).
Endogenous levels of TGF-b1 were measured in 0.5-, 5-, and 8-week differentiated 3D-WT and 3D-FAD cultures ( fig. S17A ). Considering that our 3D cultures are composed of mostly neurons, with astrocyte presence, and do not contain microglia, the endogenous TGF-b1 detected in our 3D culture models was secreted from neurons and/or astrocytes. At 0.5 week of differentiation, TGF-b1 levels were higher in the 3D-FAD cultures compared to 3D-WT. Whereas TGF-b1 levels in the 3D-WT did not differ significantly at the three time points, in the 3D-FAD culture, levels of TGF-b1 were significantly reduced in the 5-and 8-week differentiated cultures, where cell death occurred, compared to the 0.5-week differentiated cultures. When normalized by actin signal density, TGF-b1 levels in the 5-and 8-week differentiated 3D-FAD cultures did not differ from those in age-matched 3D-WT cultures ( fig. S17B) , suggesting that the decrease in TGF-b1 observed in 3D-FAD cultures compared to 3D-WT cultures was due to cell loss. However, we also observed that TGF-b1 levels normalized by actin signal were significantly lower in the 8-week differentiated 3D-FAD cultures compared to 5 week-differentiated 3D-FAD cultures. Therefore, we cannot exclude the possibility that the reduced levels observed at the 8-week time point were also attributable to specific signaling inhibitions.
Effects of ablating AHN in female 5×FAD mice AHN loss in female 5×FAD mice was accompanied by an increased number of Casp3 + cells in the DG, reduced hippocampal levels of PSD95, and exacerbated cognitive dysfunction (Fig. 6 , A to E, and fig. S18; see fig. S18A for number of animals in each experimental group and group arrangement explanations). However, these mice did not show reduced hippocampal levels of TGF-b1 (Fig.  6F) . Thus, we measured endogenous levels of TGF-b1 in the hippocampus of untreated male and female WT and 5×FAD mice at different ages (Fig. 6G) . Untreated female 5×FAD mice showed significantly increased TGF-b1 levels as compared to WT mice and increased, although not statistically significant, TGF-b1 levels as compared to male 5×FAD mice at 5 months of age. The relatively increased levels of TGF-b1 in female 5×FAD mice might mask the ability to observe a small reduction of TGF-b1, as observed in male 5×FAD mice without AHN. Therefore, blocking AHN might result in reduction of TGF-b1 in 5×FAD mice at an age when endogenous TGF-b1 levels are not yet increased as compared to WT mice. AHN loss still increased Casp3 + cell numbers in female 5×FAD mice, suggesting that reduction of TGF-b1 is most likely not the only mechanism underlying cell death in 5×FAD mice lacking AHN.
Exercise increased levels of hippocampal BDNF, PSD95, SYP, IL-6, and FNDC5 We addressed the mechanism by which the combination of exercise and increased AHN, but not increased AHN alone, improved cognition in the 5×FAD mice. Exercise has been shown to increase neurotrophins, growth factors, and synaptic markers and to reduce neuroinflammation (31) (32) (33) (34) (35) . Exercise induces fibronectin type III domaincontaining protein-5 (FNDC5) that regulates hippocampal BDNF expression in mice (36) . We first measured 18 molecules in the hippocampus of untreated sedentary and exercised 5×FAD mice and found that exercise increased the levels of hippocampal BDNF, PSD95, synaptophysin (SYP), interleukin-6 (IL-6), and FNDC5 (table S6) .
We next measured the levels of these molecules in the 5×FAD CTL , 5×FAD ProAHN , 5×FAD +AHN(RUN) , and 5×FAD yAHN(RUN) mice. Exercise again led to increased levels of hippocampal BDNF, PSD95, SYP, IL-6, and only in male mice, FNDC5, whereas activating AHN alone did not (Table 1 and table  S7 ). Considering that AD patients have reduced levels of BDNF, PSD95, and SYP (37) (38) (39) and that these proteins are important regulators of synaptic plasticity, the increase in these protein levels with exercise combined with increased AHN may contribute to an improved behavioral outcome for patients, as observed in the 5×FAD +AHN(RUN) mice. IL-6, for which levels are selectively elevated in the hippocampus following exercise (40) , has also been reported to benefit cognition and regulate neurogenesis (41) (42) (43) (44) (45) .
AHN activation combined with increased BDNF levels genetically ameliorates cognitive function in 5×FAD mice To explore the mechanisms underlying cognitive improvement after combined exercise and increased AHN, we directly increased BDNF, IL-6, or FNDC5 in the hippocampus of 5×FAD ProAHN mice. We investigated whether increasing levels of these factors in conjunction with increased AHN would result in cognitive improvements mimicking those observed in the 5×FAD +AHN(RUN) mice. To increase BDNF in the 5×FAD ProAHN In 10-month-olds, *P < 0.05 between male 5×FAD and WT mice; **P < 0.01 between female 5×FAD and WT mice.
and 5×FAD +AHN(RUN) mice (5×FAD ProAHN/LV-RFP and 5×FAD +AHN(RUN)/LV-RFP mice, respectively). LV-BDNF injection increased hippocampal BDNF levels in both 6-month-old male and female 5×FAD ProAHN mice (Fig. 7B; see table S8 for statistical analysis of Fig. 7 experiments) . Although BDNF has been shown to regulate AHN positively (46), LV-BDNF injection did not further increase the number of DCX + neurons in 5×FAD mice treated with P7C3 and LV-Wnt3, and the number of DCX + neurons was comparable in all groups (Fig. 7C) . LV-BDNF injection did not affect Ab plaque levels (Fig. 7D) .
In the Y-maze, both male and female 5× FAD +AHN(RUN)/LV-RFP mice showed improved memory compared to the 5×FAD ProAHN/LV-RFP mice of both genders (Fig. 7E and fig. S19 ).
5×FAD
ProAHN/LV-BDNF mice also exhibited similar memory improvement. In male cohorts, during the RAM task training trials, 5×FAD Fig. 2A, right  graph) . However, increasing AHN in conjunction with BDNF in female 5×FAD mice (female 5× FAD ProAHN/LV-BDNF mice) produced significantly improved pattern separation memory (Fig. 7G) .
Increasing BDNF alone, in the absence of promoting AHN by P7C3 and LV-Wnt3, failed to increase AHN or improve memory in 5×FAD mice (Fig. 7, H and I, and fig. S20 ). These results suggest that increasing hippocampal BDNF, in combination with AHN activation, is sufficient to mimic the beneficial effects of exercise on cognition in 5×FAD mice, even in the continued presence of Ab plaques.
AHN activation, combined with increased BDNF levels, pharmacologically ameliorates cognitive function in 5×FAD mice We next explored whether a late-stage increase in BDNF pharmacologically (AICAR), with increased AHN by P7C3 and LV-Wnt3, could also provide an effective therapeutic strategy comparable to that of sustained exercise in 5×FAD mice. For this purpose, we used the AMP-activated protein kinase agonist 5-aminoimidazole-4-carboxamide riboside (AICAR), which increases BDNF in mice (47) . Male and female 5×FAD ProAHN mice were injected with AICAR or saline every other day for 2 weeks starting at 5.5 months of age; they were sacrificed at 6 months of age (5×FAD ProAHN/AICAR and 5×FAD ProAHN/Veh mice, respectively). Hippocampal BDNF levels were increased in the male and female 5×FAD (Fig. 7L) . Female 5×FAD ProAHN/AICAR mice showed improved pattern separation in the DNMP task, again performing similarly to 5× FAD +AHN(RUN)/Veh mice ( Fig. 7M ). It has been reported that AICAR alone increases AHN and cognition in WT mice (47, 48) . However, AICAR alone failed to increase AHN in the 5×FAD mice, although it increased hippocampal BDNF levels ( fig. S22A ). No effect of AICAR was observed in the cognition tasks that we employed in 5×FAD mice with no AHN activation ( fig. S22B-S22D ). These results suggest that a late-stage increase in BDNF by AICAR, in the presence of promoted AHN, could mimic the beneficial effects of exercise on cognition in 5×FAD mice.
Future studies will be needed to explore the mechanisms by which increasing levels of BDNF and AHN combine to mimic the benefits of exercise on cognition in AD. LV-BDNF injection increased levels of hippocampal PSD95, whereas AICAR did not (table S9) . Neither LV-BDNF nor AICAR increased IL-6 levels (table S9). These results suggest that the beneficial effects of increasing both AHN and BDNF on cognition could be independent of PSD95 or IL-6. Directly increasing levels of hippocampal IL-6 or FNDC5 via lentivirus failed to improve cognition or increase BDNF in 5×FAD ProAHN mice. However, it is possible that only the secreted form of peripherally expressed FNDC5 is responsible for exercise-induced hippocampal BDNF, as peripheral delivery of FNDC5 induces the expression of hippocampal BDNF (36) . There may be other possible effects of AICAR aside from increasing BDNF levels. TGF-b1 levels were not changed by increasing AHN with or without increased BDNF, increasing BDNF only, or by exercise in our study (table S10).
Discussion
In the present study, we did not explore the effects of AHN manipulation on tau phosphorylation levels because basal tau phosphorylation is already present in adult-generated neurons at DCX + immature neuronal stages [(49); see fig.  S23 ]. Future studies are necessary to investigate whether adult-generated neurons affect tauopathy in the human AD brain. The effects of physical exercise on cognition in patients with dementia are inconclusive (50) (51) (52) improvement in memory. These data suggest that promoting AHN can ameliorate AD pathology and cognitive deficits but only in the presence of a healthier, improved local brain environment, e.g., stimulated by physical exercise. Increasing AHN alone (genetically and pharmacologically) combined with overexpression of BDNF was able to mimic exercise-induced improvements in cognition, without reducing Ab burden. We also found that deficits in AHN in very early stages of life can exacerbate neuronal vulnerability in AD later in life, leading to cognitive impairment and increased neuronal loss, due at least in part to reduced TGF-b1. These results suggest that adult-born neurons generated very early in life are critical for maintaining hippocampal neuronal populations in the abnormal and hostile brain environment created by AD later in life. Thus, AHN impairment may be a primary event that later mediates other aspects of AD pathogenesis. Future attempts to create pharmacological mimetics of the benefits of exercise on both increased AHN and the health of the local neuronal environment, especially involving increased BDNF levels, may someday provide an effective means for improving cognition in AD. Moreover, increasing neurogenesis in the earliest stages of AD pathogenesis may protect against neuronal cell death later in the disease, providing a potentially powerful diseasemodifying treatment strategy for AD.
Materials and Methods Animals
We used 5×FAD APP/PS1 doubly transgenic mice that co-overexpress and co-inherit FAD mutant forms of human amyloid precursor protein (APP) (the Swedish mutation: K670N, M671L; the Florida mutation: I716V; the London mutation: V717I) and presenilin 1 (PS1) (M146L; L286V) transgenes under transcriptional control of the neuronspecific mouse Thy-1 promoter (Tg6799 line). 5×FAD lines (B6/SJL genetic background) were purchased from Jackson Laboratory and were maintained by crossing heterozygous transgenic mice with B6/SJL F1 breeders. All 5×FAD transgenic mice were heterozygotes with respect to the transgene. Animal experiments were conducted in accordance with institutional and NIH guidelines.
Observed benefits of employing the 5×FAD mouse model
Most of the current AD transgenic mouse models are generated by the overexpression of mutation (s) related to familial AD (FAD). While the 5× FAD mouse model expresses rare early-onset FAD mutations, the pathological features found in the brains of 5×FAD mice are common to all forms of AD. In the current study, we examined the manner in which altered AHN affects cell survival and cognition under these pathological conditions. Hence, we believe that the results of our experiments are also relevant for generalized AD pathology (beyond that of early-onset FAD). We chose 5×FAD mice, which show faster AD progression compared to other AD transgenic mice, based on our goal of investigating whether impaired AHN at an early stage in AD resulted in neuronal/synaptic loss and in accelerated cognitive impairment at later stages of the disease. We also aimed to investigate whether adultgenerated neurons affected the pre-existing neuronal populations and whether impaired AHN exacerbated neuronal loss in AD.
5×FAD mice are one of the few AD transgenic mouse models that exhibit neurodegeneration, thus rationalizing our use of this model. In addition, performing long-term manipulations of AHN is challenging and can compromise the health of mice over time. For example, multiple irradiations cause neuro-inflammation. Longterm injections of TMZ cause side effects, including weight loss and hair loss (personal observations). Lentivirus is delivered to the brain using stereotaxic surgery, and multiple brain surgeries are not possible. Thus, studying the 5×FAD line, which undergoes more rapid AD progression compared to other AD transgenic mice, is advantageous for our study.
Generation of LV-Wnt3 and LV-dnWnt
To construct the Wnt3-Internal ribosomal entry site (IRES)-GFP vector, we cloned the cDNA of Wnt3 upstream of the IRES and GFP and inserted the bicistronic cassette in place of the GFP sequence in the pRRL.SIN.cPPT.hPGK.GFP.Wpre vector. To generate the dnWnt-IRES-GFP vector, we cloned the cDNA for dnWnt upstream of the IRES and GFP and inserted the bicistronic cassette in place of the GFP sequence in the CSC. cPPT.hCMV.GFP.Wpre vector. Concentrated lentiviral stocks were produced by calcium phosphate transfection into 293T cells. Supernatants were collected, passed through a 0.22-mm filter, and purified by ultracentrifugation. Viral stocks were stored at −80°C until use and were diluted at 0.8 × 10 9 to 1 × 10 9 transducing units/ml.
Treatment of aminopropyl carbazole (P7C3) and LV-Wnt3, and exercise setting
To increase neurogenesis, 2-month-old 5×FAD mice received 20 mg/kg of P7C3 (Sigma, St. Louis, MO; Asinex, Winston-Salem, NC) once daily for 4 or 5 days a week intraperitoneally (i.p.) over the span of 4 to 4.5 months. P7C3 was prepared for dosing by dissolving a recrystallized stock in dimethyl sulfoxide (DMSO) at 50 mg/ml. The compound was diluted to a final formulation of 3% DMSO/10% cremophor EL (Sigma, St. Louis, MO)/87.5% D5W (5% dextrose in water, pH 7.2). At the age of 3 months, these mice also received 4 intrahippocampal injections of 0.5 ml (total 2.0 ml) LV-Wnt3 viral suspension at these coordinates: AP, −2.0; ML, ±1.5-1.7; DV, −2.0 and AP, −3.0; ML, ±3.0; DV, −3.0. Injections were performed using a 5 ml Hamilton syringe with a 30-gauge needle attached to a digital stereotaxic apparatus and an infusion pump at a rate of 0.15 ml/min. After virus infusion was completed, the needle remained in place for 10 min before slow withdrawal. The mice were not injected with P7C3 both 3 days prior to and following the LVWnt3 injection day. Control 5×FAD mice received vehicle solution [3% DMSO/10% cremophor EL (Sigma, St. Louis, MO)/87.5% D5W (5% dextrose in water, pH 7.2) with no P7C3] and LV-GFP. Both groups were either singly housed either in standard laboratory cages (27 cm by 11 cm by 17 cm) only or singly spent 3 hours in rat cages (45 cm by 20 cm by 20 cm) without running wheels and then were returned to their original cages for 21 hours. A cohort of control 5×FAD mice treated with vehicle and LV-GFP singly spent 3 hours in rat cages equipped with running wheels and was returned to their original cages for the remaining 21 hours, as described previously (11) , from between the ages of 6 weeks and 2 months until the end of the experiments.
To evaluate potential changes in neurogenesis, we determined the number of DCX + cells in the targeted (GFP-expressing) areas. Areas infected by LVs were identified by expression of GFP.
Blocking AHN
To block AHN, 1.5-to 2-month-old WT and 5×FAD mice received IR, TMZ or LV-dnWnt and were sacrificed at 3 or 5 months of age. Irradiation was not used for mice that were sacrificed at 3 months of age because it requires~1 month of recovery time. Additional 4-to 4.5-month-old 5×FAD mice received TMZ or LV-dnWnt and were sacrificed at 5 months of age.
Irradiation procedure
Mice were anesthetized with ketamine and xylazine, placed in a stereotaxic frame, and put into a custom-made radiation shield consisting of a chamber with 1-inch-thick lead and a 2.5-mm borehole. The shield covered the entire body but left a 2.5-mm treatment field above the hippocampus. Mice received irradiation once at the dose of 1000 cGy, administered at~90 cGy per minute for a total irradiation time of 11 min. A Gammacell 40 Exactor (Theratronics, Ottawa, Ontario) with two cesium-139 sources was used.
TMZ injection
The DNA-alkylating agent TMZ (Merck & Co., Inc., Whitehouse Station, NJ; Sigma, St. Louis, MO) was dissolved in phosphate-buffered saline (PBS) or in DMSO followed by diluting in PBS to a concentration of 2.5 mg/ml (10% DMSO for TMZ from Sigma). TMZ was administered i.p. at a dose of 12.5 mg/kg once daily for 3 consecutive days, followed by 4 days of no injections (one cycle). After every four cycles, mice were given a 2-week rest period. Vehicle solution was the identical DMSO/PBS solution but without TMZ and was administered in volumes consistent with TMZ dosing.
LV-dnWnt injection
Stereotaxic injections of LV-dnWnt were performed as described above for LV-Wnt3 injections.
Injections of LV-TGF-b1 and LV-BDNF
LV-TGF-b1, LV-BDNF, LV-IL-6, IL-FNDC5, and control LV-RFP were purchased from ViGene Biosciences (Rockville, MD). 5×FAD Sham , 5×FAD IR , 5×FAD Veh , and 5×FAD TMZ mice received four intrahippocampal injections of 0.5 ml (total 2.0 ml) of LV-TGF-b1 or LV-RFP viral suspension (AP, −2.0; ML, ±1.5 to 1.7; DV, −2.0 and AP, −3.0; ML, ±3.0; DV, −3.0) at the age of 2.5 to 3 months. For injections of LV-dnWnt along with LV-TGFb1 or LV-RFP in 5×FAD mice, 1.5-to 2-month-old mice received four intrahippocampal injections of total 2.4 to 3.0 ml of LV-dnWnt with LV-TGFb1 or LV-RFP viral suspension. For injection of LV-BDNF, 5×FAD ProAHN mice received LV-BDNF at the age of 3 months when they received LVWnt3: total 2.4 to 3.0 ml of LV-Wnt3 with LV-BDNF or LV-RFP viral suspension.
Treatment of 5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside (AICAR)
Mice were injected (i.p.) with AICAR (Toronto Research Chemicals Inc., Canada) dissolved in saline, 250 mg/kg per day, or with saline, every other day for 2 weeks. During the 2 weeks, P7C3 was not injected.
5-Bromo-2'-deoxyuridine (BrdU) injections
BrdU (Sigma, St. Louis, MO) was dissolved in 0.9% NaCl at a concentration of 20 mg/ml and was filtered (0.2 mm) under sterile conditions. Mice received a single i.p. injection of BrdU (50 mg/kg) daily for 3 days and were perfused 1 day after the last BrdU injection and processed for BrdU immunostaining to identify proliferating neural progenitor cells (NPCs). Parallel cohorts of animals from each group were sacrificed 4 weeks after the last BrdU injection and processed to determine the rate of NPC survival and differentiation.
Behavior tests
We performed three different behavioral tests: a delayed nonmatching to place (DNMP) task to measure pattern separation, an eight-arm radial arm maze (RAM) to measure reference memory and retention memory, and a Y-maze to measure short-term spatial (working) memory. For the DNMP and RAM tasks, mice were food restricted to 90% of their pre-experimental freefeeding weights with water available ad libitum. We confirmed that our food deprivation regime did not affect AHN in WT and 5×FAD mice. Behavior analyses were performed blindly.
DNMP task
Pattern separation-dependent memory was tested in the DNMP task in the RAM apparatus as described previously (16) with modifications. The testing apparatus was a rat-sized RAM. The maze consisted of eight equally spaced arms that radiated from an octagonal central platform. Arms were 15 cm wide by 75 cm long, and the walls on each arm were 2.5 cm high. On the morning before testing commenced, mice were habituated to the maze, where all arms were unblocked and all wells at the end of the arms contained several sunflower seeds. Mice were allowed to explore the maze freely during this habituation session for 30 min. Each trial of this task consisted of a sample phase and a choice phase.
During the sample phase, all arms except a start arm and the sample (rewarded) arm were blocked off. Each mouse was permitted to visit the sample arm and retrieve a food pellet reward. Mice were retrieved from the maze after either (1) spending 10 s in the sample arm after retrieving the pellet or (2) exiting the sample arm. During the choice phase, arms in the start and sample (unrewarded) locations and an additional correct (rewarded) location were open. The correct arm was distant from the sample arm by a spatial separation of two arms. In this phase, mice were tested for the ability to select, from a choice of two arms, the arm location that had not been presented in a previous sample phase. Mice that entered the correct (new, rewarded) arm were considered to have made correct choices. Mice that entered an incorrect (familiar, unrewarded) arm were allowed to self-correct. Mice went through four trials (sample plus choice phases) per day for 3 consecutive days.
RAM
The RAM was used for testing spatial reference and retention memory. To adapt to the maze and bait (pretraining), the mice experienced free movement and feeding in a RAM twice a day for 2 days. The bait was scattered in all arms and a sunflower seed in a food cup was available at the end of each arm. The training trial was started following the pretraining. During the training trial, each mouse was given two trials daily for 5 days. The same two arms were baited each day and across sessions; thus mice learned to ignore the remaining six arms that never contained a reward. A trial consisted of placing the mouse in the maze where it remained until both of the two reinforcements had been received or until 5 min had elapsed, whichever occurred first. Entry into a never-baited arm was considered a reference memory error, and choices of arms were recorded. Memory retention trial was conducted 3 days after the last training trial in the reference memory test of RAM task.
Y-maze
Short-term spatial memory was assessed by recording spontaneous alternation behavior in a Y-maze, which does not involve any training, reward, or punishment. The ability to alternate requires mice to know which arms have already been visited. Therefore, alternation behavior can be regarded as a measure involving spatial working memory. Each mouse was placed in the center of the symmetrical Y-maze and was allowed to explore freely through the maze during an 8-min session. The sequence and total number of arms entered were recorded. Arm entry was considered to be complete when the hind paws of the mouse had been completely placed in the arm. An alternation was defined as entries into all three arms on consecutive occasions. The number of maximum alternation was therefore the total number of arm entries minus 2, and the percentage of alternation was calculated as (actual alternations / maximum alternations) × 100.
Tissue processing
After behavioral tasks, mice were deeply anesthetized with a mixture of ketamine and xylazine and then decapitated. Isolated brains were bisected longitudinally and hemispheres were separated. Hippocampal tissues were dissected from the left hemisphere and frozen on dry ice for biochemical studies. The right hemisphere was kept in 4% paraformaldehyde (PFA) in cold 0.1 M phosphate buffer (pH 7.4) for 3 days, followed by incubation in 30% sucrose solution for immunostaining. Mice injected with BrdU were deeply anesthetized with a mixture of ketamine and xylazine, and perfused transcardially with 4% PFA in cold 0.1 M phosphate buffer (pH 7.4) after 0.9% NaCl. The brains were postfixed overnight and then transferred into a 30% sucrose solution and kept there until they sank. For immunostaining, 40-mm coronal sections were cut from a dry ice-cooled block on a sliding microtome (Leica, Wetzlar, Germany). The sections were stored at −20°C in a cryoprotective buffer containing 28% ethylene glycol, 23% glycol, and 0.05 M phosphate buffer until processing for immunohistochemistry or immunofluorescence.
Immunohistochemistry and immunofluorescence confocal microscopy
Immunohistochemistry and immunofluorescent labeling were performed as described previously (54) . The antibodies used were rat anti-BrdU The immunohistochemical staining was made using the avidin-biotin complex (ABC) system and nickel-enhanced diaminobenzidine (DAB) incubation (Vectastain Elite, Vector labs, Burlingame, CA). Sections were mounted on gelatincoated slides, air-dried, dehydrated, cleared, and coverslipped. The fluorescent secondary antibodies used for immunofluorescent labeling were donkey anti-goat immunoglobulin G (IgG) conjugated with Cy2 or Cy3; donkey anti-rat IgG conjugated with Cy2 or Cy3; donkey anti-mouse IgG conjugated with Cy2 or Cy3 or Cy5; donkey anti-rabbit IgG conjugated with Cy2 or Cy3 or Cy5 (all 1:250, Jackson ImmunoResearch, West Grove, PA). Fluorescent signals were detected using a LSM Pascal 5 Carl Zeiss confocal laser scanning microscope (Zeiss, Germany). Images were captured and recorded using a Zeiss LSM image browser.
For BrdU staining, DNA was denatured by incubating the sections for 2 hours in the 50% formamide/2× SSC (0.3 M NaCl and 0.03 M sodium citrate) at 65°C. Sections were rinsed for 15 min in 2× SSC and incubated for 30 min in 2 N HCl at 37°C. Acid was neutralized by rinsing the sections for 10 min in 0.1 M boric acid (pH 8.5) followed by several washes in Tris-buffered saline (TBS, pH 7.5).
Quantification of immunoreactivity and mouse regrouping
For estimating total BrdU + cells, a series of systematically selected every sixth brain section was stained, and BrdU + cells in the subgranular cell layer (SGL) and granular cell layer (GCL) were counted by collecting images under 40× objective on a light microscope (TE360 Eclipse, Nikon, Japan) or a confocal microscope (LSM Pascal 5 Carl Zeiss, Germany). The sum of the BrdU + cell counts was multiplied by 6 to obtain an estimate of total numbers. For co-labeling analysis of differentiated BrdU + cell types with lineage-specific markers, the phenotypes of 30 BrdU + cells per animal were determined. Both the BrdU + cell count and the phenotype analysis were performed blindly.
For quantification of DCX + cells, a series of systematically selected every 6th or 12th brain section from each mouse was taken from similar regions spanning between bregma −1.34 mm and −3. For quantification of Casp3 + cells, a series of systematically selected every sixth brain section was stained, and Casp3 + cells in the SGL and GCL were counted by collecting images under 40× objective on a light microscope (TE360 Eclipse, Nikon, Japan) or a confocal microscope (LSM Pascal 5 Carl Zeiss, Germany). The sum of the Casp3 + cell counts was multiplied by 6 to obtain an estimate of total numbers. Researchers who were unaware of the experimental group to which the samples belonged quantified DCX + or Casp3 + cells.
Total granule cell counting
Granule cell numbers were determined using unbiased stereologic counting methods. Each sixth section containing the hippocampus was Nissl stained. Optical disector frames (15 × 15 mm) were set in as systematic-random fashion, accounting for 1% of the area of the GCL on each section. Cells were counted in 5-mm-thick stacks of optical disectors (1 mm in depth for each disector), according to stereologic principles. The total number of GCL neurons was obtained by using the formula developed as described previously (55) . The granule cell counting was performed blindly.
Quantitative assessment of amyloid deposition
To examine the impact of AHN manipulation or exercise on amyloid deposition, a series of systematically selected (every 12th) brain sections from each mouse was probed with Ab-specific 3D6 antibodies, detected by fluorescently labeled secondary antibodies. Images to quantify the amyloid burden were collected in a Z series of 40-mm depth with 4-mm intervals between images. The volume of amyloid burden was quantified using ImageJ (Voxel counter plugin), and the area of Ab immunoreactivity was assessed after adequate thresholding and isolated noise despeckling.
Quantitative cytokine level measurement and ELISAs
Hippocampal tissues were homogenized in RIPA buffer (Sigma, St. Louis, MO) and centrifuged at 45,000g for 30 min at 4°C. Supernatants were used to measure 10 cytokines: Interleukin 1b (IL1b), IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, tumor necrosis factor a (TNFa), interferon-g (IFN-g), and keratinocyte-derived chemokine (KC/GRO). The measurement of cytokines was performed using the MesoScale Discovery (MSD, Rockville, MD) 96-well Mouse Pro-Inflammatory V-PLEX Assay as outlined in the manufacturer's protocol. Briefly, 25 ml each of sample and calibrator were added to the plate coated with an array of cytokine capture antibodies. The plate was then incubated for 2 hours with vigorous shaking at room temperature, followed by washing with wash buffer (provided in the kit). A volume of 25 ml of the detection antibody solution was added and incubated for 2 hours with vigorous shaking at room temperature. The plate was washed with wash buffer before adding 150 ml 2× MSD Read Buffer, and immediately read on a Meso QuickPlex SQ 120. For TGF-b1, PSD95, SAP97, SYP, and FNDC5 analyses, supernatant samples were further diluted in cold PBS. For TGF-b1, diluted samples were acidified to pH < 3 with 1 N HCl and incubated for 1 hour at room temperature, followed by neutralization to pH~8 with 1 N NaOH. Levels of TGF-b1 were measured using TGF-b1 Platinum ELISA kits (Affymetrix eBioscience, San Diego, CA) according to the manufacturer's protocols. PSD95, SAP97, SYP, and FNDC5 contents were measured using ELISA kits from MyBioSource (San Diego, CA) according to the manufacturer's protocols. BDNF protein levels were measured using BDNF ELISA kits (R&D Systems, Minneapolis, MN). TGF-b1 in the media of the 3D cultures were measured using the MSD 96-well TGF-b1 kit (Rockville, MD).
Immunoblot analysis
Fifteen to 75 mg of protein were resolved on 12% Bis-Tris or 4 to 12% gradient Bis/Tris gels (Life Technologies, Grand Island, NY), and the proteins were transferred to the nylon membranes (Bio-Rad, Hercules, CA). Immunoblot images were visualized by enhanced chemiluminescence (ECL). The images were captured by using BioMax film (Kodak, Rochester, NY) or VersaDoc imaging system (Bio-Rad, Hercules, CA) and quantitated by using QuantityOne software (Bio-Rad, Hercules, CA). Primary antibodies were used at the following dilutions: anti-PSD95 (1:500, NeuroMab, Davis, CA), anti-synapse-associated protein 97 (SAP97, 1:500, NeuroMab, Davis, CA), and anti-synaptophysin (SYP, 1:1,000, Millipore, Temecula, CA).
Golgi staining
Golgi staining was performed using the FD Rapid Golgi Stain Kit (FD Neurotechnologies, Inc., Columbia, MD), a simplified and reliable kit for Golgi impregnation, to label neurons in the outer layer of GCLs. Animals were deeply anesthetized with an isoflurane, and the brains were immediately removed and rinsed in MilliQ water. After the rinse, retrieved brains were immersed in a Golgi-Cox solution comprising potassium dichromate, mercuric chloride, and potassium chromate. This mixture of solutions was replaced once after 6 hours of initial immersion, with storage at room temperature in darkness for 2 weeks. After the immersion period in the Golgi-Cox solution, the embedded brains were transferred to a cryoprotectant solution (FD Rapid Golgi Stain Kit) and stored at room temperature for at least 72 hours in the dark before cutting. The brain slices were sectioned in the coronal or sagittal plane at approximately 250 mm thickness on a cryostat. Sliced tissues were transferred onto gelatin-coated slides and were air dried at room temperature in the dark. After drying, sections were rinsed with distilled water and were subsequently stained in a developing solution (FD Rapid Golgi Stain Kit) and dehydrated with 50, 75, 95, and 100% ethanol. Finally, the sections were defatted in xylene substitute and coverslipped with either Permount (Fisher Scientific, Fair Lawn, NJ).
Images were acquired from prepared slides using a Zeiss 510 microscope. Each neuron was scanned under high (100×, oil immersion) magnification by varying the depth of the Z plane to ensure that all parts of the cell (especially dendrites) were intact. Dendrites that tapered to a point were assumed to be complete and uncut. At least 20 neurons were selected. 3D neuronal reconstruction was performed by LSM510 (Zeiss). The total length and number of branches of dendrites and the spine density were measured by Imaris software (Bitplane, Concord, MA). Seven neurons per mouse were examined.
Treatment of 3D FAD ReN cell cultures with TGF-b1
ReNcell VM human NPCs (ReN cells, EMD Millipore, Billerica, MA) were transfected with internal ribosome entry site (IRES)-mediated polycistronic lentiviral vectors containing FAD genes encoding human APP with both Swedish (K670N/ M671L) and London (V717I) mutations, or PS1DE9 mutation along with APP Swedish/London mutations, with GFP as a reporter for viral infection. Fluorescence-activated cell sorting (FACS) was then used to enrich the population of cells with the highest expression levels. ReN cells with GFP alone served as controls. The FACS-sorted ReN cells expressing high levels of FAD genes were differentiated and maintained in a 3D Matrigel culture system. Differentiation media containing either 1, 5, or 10 ng/ml of active human TGF-b1 (Abcam, Cambridge, MA) were added to 6-week differentiated cultures every 3 days, and the cells were maintained for an additional 2 weeks. The cell media were collected for Lactate dehydrogenase (LDH) assay, CellTiter-Glo luminescent cell viability assay and Ab quantification. The cells were fixed with 4% PFA for Casp3 staining.
LDH assay
CytoTox-ONE assay was performed according to the manufacturer's guidelines (Promega, Madison, WI). Fifty microliters of cell culture medium was removed from the cells and substrate was added to the cell culture medium in 1:1 dilution and incubated for 30 min in a 37°C incubator. The plate was measured using a spectrophotometer (excitation: 560 nm, emission: 590 nm). Under the influence of the assay's substrate, resazurin is converted to the fluorescent form resorufin due to LDH, which is released into the medium by dead cells only. Therefore, increased values during the experiments were interpreted as increased cell death.
CellTiter-Glo luminescent cell viability assay
Cell viability was determined using the CellTiterGlo luminescent cell viability kit from Promega Corporation (Madison, WI) according to the manufacturer's instructions. This method was based on the measurement of ATP production in the cells, which is proportional to the number of viable cells, detected by luciferin-luciferase reaction. One hundred microliters of CellTiterGlo Reagent was added into the wells. Contents were mixed for 2 min on an orbital shaker to induce cell lysis. The plate was allowed to incubate at room temperature for 10 min to stabilize luminescent signal, and luminescence was recorded.
Casp3 staining using 3D cultures
The fixed cells were permeabilized and blocked by incubating with a blocking solution containing 50 mM Tris (pH 7.4), 0.1% Tween-20, 4% donkey serum, 1% BSA, 0.1% gelatin, and 0.3 M glycine at 4°C for 12 hours. After washing with TBS buffer containing 0.1% (v/v) Tween-20 (TBST), the 3D cultures were incubated with rabbit monoclonal anti-cleaved Casp3 (1:1,000, Cell signaling, Danvers, MA) antibodies in the blocking solution at 4°C overnight. After washing three times with TBST, the cells were incubated with donkey anti-rabbit IgG conjugated Cy3 for 2 hours at room temperature (1:250, Jackson ImmunoResearch, West Grove, PA). To avoid fluorescence quenching, a drop of anti-fade gold (Life Technologies, Grand Island, NY) was added on top of the fixed/stained thin-layer 3D cultures before imaging.
Dot-blot analysis
3D Matrigel samples were dissolved in Lysis Buffer 6 (R&D Systems, Minneapolis, MN) with protease and phosphatase inhibitors (Thermo Scientific, Rockford, IL). One microliter of each sample was spotted onto a LI-COR Biosciences Odyssey Nitrocellulose Membrane (LI-COR Biosciences, Lincoln, NE). The dot blot was then stained for Monoclonal Anti-b-Actin-Peroxidase antibody produced in mouse (Sigma Aldrich, St. Louis, MO) overnight at a dilution ratio of 1:50,000. Then, after sufficient washing the following day, the blot was coated with 2 ml of Pierce ECL Western Blotting Substrate (Thermo Scientific, Rockford, IL). Chemiluminescent detection imaging was then conducted using the Chemi exposure setting on a Li-Cor Odyssey FC machine (LI-COR Biosciences, Lincoln, NE) and then quantified using Image Studio software (LI-COR Biosciences, Lincoln, NE).
Statistical analysis
Data are expressed as mean values ± standard error of the mean (mean ± SEM). Error bars in the figures represent SEM. Differences between groups were analyzed using a t-test or an ANOVA that was followed by a post hoc comparison using Tukey or Fisher's least significant difference (LSD), where appropriate. For the RAM tests, a two-way repeated measures analysis of ANOVA was used for main effects (groups) with day as the repeated measure and errors as the dependent variable. In all cases, values of P < 0.05 were considered to be significant, and * or # indicated P < 0.05 and ** or ## indicated P < 0.01. Statistical analysis was performed using PRISM GraphPad statistical software.
